Skip to main content

Health condition · Clinically reviewed

Bullous pemphigoid, tense blisters, itch and the modern topical-first plan.

The most common autoimmune blistering disease in older adults. A stepped approach - starting with a super-potent topical steroid and stopping any trigger drug - controls the majority of patients.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NICE, BAD and peer-reviewed dermatology sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including super-potent topical steroids, doxycycline and rituximab for refractory disease.

Key facts

Bullous pemphigoid at a glance.

The essentials, in plain English - what it is, who gets it, and how UK dermatologists treat it in 2026.

  • What it is

    The most common autoimmune blistering skin disease in the Western world - IgG (and IgE) autoantibodies target BP180 and BP230 hemidesmosomal proteins.

  • Who it affects

    Mostly the elderly - peak incidence above 70, mean 70 to 80, men and women equally. Incidence is rising as the population ages.

  • What happens

    Autoantibodies split the dermoepidermal junction, producing tense subepidermal blisters on urticarial or normal skin.

  • Common triggers

    DPP-4 inhibitor gliptins (vildagliptin, linagliptin, sitagliptin), spironolactone, furosemide, checkpoint inhibitors, radiotherapy and UV.

  • Foundation therapy

    Super-potent topical clobetasol is first-line for most patients - as effective as oral steroids with fewer side effects.

  • When to escalate

    Oral prednisolone, doxycycline-niacinamide, azathioprine, methotrexate, mycophenolate or rituximab for severe or refractory disease.

Why this guide matters

Topical first, then a careful ladder.

Bullous pemphigoid used to mean high-dose steroids for months. Modern UK practice starts with super-potent topical steroids and reserves oral immunosuppression for those who truly need it.

  • Topical clobetasol is first-line

    A super-potent topical steroid applied over the whole body is as effective as oral prednisolone in landmark trials, with far fewer side effects.

  • Stopping the trigger drug matters

    DPP-4 inhibitor gliptins, spironolactone and checkpoint inhibitors can precipitate disease - stopping the culprit sometimes resolves it.

  • Steroid-sparing agents change lives

    Doxycycline with niacinamide, azathioprine, methotrexate, mycophenolate and now rituximab reduce steroid burden and long-term harm.

How the diagnosis is made

From first itch to a confirmed diagnosis.

The steps a UK GP and dermatologist will normally follow - clinical assessment, biopsy for H&E and immunofluorescence, and serology.

  1. 01

    Assessing

    Clinical assessment

    A close look at the tense bullae, urticarial prodrome, distribution (flexures, trunk, limbs) and mucosal involvement.

  2. 02

    Assessing

    Medication review

    A careful trawl for triggers - especially DPP-4 gliptins, spironolactone, furosemide, penicillins, sulfa drugs and immune checkpoint inhibitors.

  3. 03

    Assessing

    Rule out other bullous disease

    Nikolsky sign is negative in bullous pemphigoid - a positive sign points to pemphigus vulgaris and needs different treatment.

  4. 04

    Confirming

    Skin biopsy for H&E

    Lesional skin shows a subepidermal blister with eosinophils - the histological signature of bullous pemphigoid.

  5. 05

    Confirming

    Direct immunofluorescence

    Perilesional skin shows linear IgG and C3 at the dermoepidermal junction - the gold-standard test that confirms the diagnosis.

  6. 06

    Confirming

    Serology - IIF and ELISA

    Indirect immunofluorescence on salt-split skin (roof binding) and ELISA for BP180 and BP230 antibodies confirm the target and track activity.

  7. 07

    Preparing

    Bloods and screening

    FBC often shows eosinophilia with a raised IgE. Age-appropriate cancer screening is considered, though the paraneoplastic link is weaker than in pemphigus.

Typical timeline: from first blister to biopsy-confirmed diagnosis in one to two weeks.

Symptoms

What bullous pemphigoid looks like.

The classic pattern is weeks of intense itch and urticarial patches, followed by tense blisters on the flexures and trunk. Mucosal disease is uncommon.

  • Urticarial prodrome

    Itchy, red, hive-like or eczema-like patches for weeks or months before the first blister appears.

  • Intense pruritus

    Relentless itch that often precedes blistering and disturbs sleep, mood and appetite in older patients.

  • Tense bullae

    Firm, fluid-filled blisters on red or normal skin - they do not rupture as easily as pemphigus blisters.

  • Flexural distribution

    Groin, axillae, inner thighs, trunk and limbs - typically sparing the head and neck.

  • Heals without scarring

    Because the split is below the epidermis but above the dermis, healed blisters usually leave pigmentation but no scars.

  • Mucosal involvement uncommon

    Around one in five patients has oral lesions - eyes are affected less often. Widespread mucosal disease should prompt other diagnoses.

  • Nikolsky sign negative

    Gentle sideways pressure does not shear the skin - a contrast with pemphigus vulgaris, where Nikolsky is positive.

  • Red flag - frailty and infection

    Widespread blistering in an older patient risks sepsis, fluid loss and malnutrition - a low threshold for admission is right.

Treatment

How bullous pemphigoid is treated in the UK.

Super-potent topical steroids first, oral prednisolone for severe disease, and a steroid-sparing ladder from doxycycline to rituximab for those who need it.

  • Stop the DPP-4 inhibitor

    If the patient is on vildagliptin, linagliptin or sitagliptin, discontinuing it (with a diabetes team plan) can resolve the disease.

  • Super-potent topical steroid

    Clobetasol 0.05% cream, 30 to 40 g a day over the whole body, is first-line for mild-to-moderate and often extensive disease.

  • Oral prednisolone

    For severe, extensive or refractory disease - typically 0.5 to 1 mg/kg/day, tapered slowly over six to twelve months.

  • Doxycycline and niacinamide

    Doxycycline 200 mg with niacinamide 500 to 1500 mg - a steroid-sparing option with a better safety profile in frailer patients.

  • Azathioprine, MMF or methotrexate

    Conventional immunosuppressants used to reduce or stop long-term steroids in more active or relapsing disease.

  • Dapsone

    A selective option in some patients, particularly where eosinophil-rich inflammation is prominent - needs G6PD testing first.

  • Rituximab

    Anti-CD20 monoclonal antibody for refractory or severe disease - increasingly used earlier under specialist dermatology care.

  • IVIg, PLEX, omalizumab, dupilumab

    IVIg, plasma exchange and biologics targeting IgE (omalizumab) or IL-4/IL-13 (dupilumab) are emerging options for refractory disease.

Adjuncts and multidisciplinary care

Wound care, emollients, topical antimicrobials, PPI cover, bone protection with calcium, vitamin D and a bisphosphonate, blood-sugar monitoring and mood review all matter. Dermatology, tissue viability, dietitians, physiotherapy, pharmacy and geriatric medicine share the load - with palliative input where appropriate.

What this guide is based on

The sources behind every claim on this page.

UK national guidance, specialist society standards and landmark trials, current at the time of last review.

Key references

Guidelines and trials we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or dermatologist knows your skin and medical history and can tell you which parts apply to you. If you have new blistering, get seen.

  • British Association of Dermatologists (BAD). Guidelines for the management of bullous pemphigoid.

  • NICE Clinical Knowledge Summaries. Blistering skin conditions.

  • Joly P et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. New England Journal of Medicine.

  • Williams HC et al. Doxycycline versus prednisolone as an initial treatment for bullous pemphigoid (BLISTER trial). The Lancet.

  • MHRA. Drug safety updates on DPP-4 inhibitors and bullous pemphigoid.

Red flags

When bullous pemphigoid needs urgent attention.

Most patients are managed in a dermatology clinic. These are the features that need same-week specialist review or hospital admission.

  • Widespread new blistering

    Rapidly extending bullae in an older person needs same-week specialist review to prevent sepsis and dehydration.

  • Signs of infection or sepsis

    Fever, spreading redness, foul-smelling exudate or systemic upset need urgent assessment and often admission.

  • Ocular involvement

    Sore, gritty or red eyes with blistering deserve ophthalmology input - untreated mucosal disease can scar the ocular surface.

  • Severe oral disease

    Extensive mouth blisters that stop the patient eating or drinking risk malnutrition and dehydration - review promptly.

  • On a DPP-4 inhibitor

    Vildagliptin, linagliptin and sitagliptin have a strong association with bullous pemphigoid - flag the medication early.

  • Frailty and comorbidity

    Age, cardiac disease and cognitive impairment worsen prognosis - integrate geriatrics and palliative input where appropriate.

  • Steroid complications

    Hyperglycaemia, blood pressure rises, mood changes, infection and osteoporosis need active monitoring and prevention.

  • Nikolsky positive skin

    If gentle shear splits the skin, think pemphigus vulgaris rather than bullous pemphigoid - the workup and treatment differ.

  • Suspected drug-induced disease

    New blistering within weeks of a checkpoint inhibitor or other trigger should prompt urgent oncology or dermatology review.

Living with it

A relapsing condition, with a clear plan.

Four things that make the biggest difference day to day - gentle skin care, protecting against steroid side effects, eating well, and planning for relapse.

A quiet reminder

Small daily habits protect fragile skin.

Emollients, careful handling, prompt dressing changes and early antibiotics for infection prevent most of the complications that put patients in hospital.

  1. 01 Skin care

    Keep the skin barrier calm

    Bland emollients, gentle cleansing and clean dressings on eroded areas reduce itch and infection risk.

  2. 02 Steroids

    Protect against side effects

    Bone protection, blood-sugar checks, blood-pressure monitoring and gastric protection all matter during oral steroid courses.

  3. 03 Nutrition

    Eat well, drink well

    Blistering is a protein-losing dermatosis - dietitian input helps prevent weight loss and healing delays.

  4. 04 Follow-up

    Plan for relapse

    Bullous pemphigoid often relapses - a clear plan for who to call and how to restart treatment shortens flares.

Frequently asked

Everything we get asked about bullous pemphigoid.

Quick answers on symptoms, drug triggers, biopsy, topical steroids and long-term prognosis.

  • What is bullous pemphigoid?

    Bullous pemphigoid is the most common autoimmune blistering skin disease in the Western world. IgG (and often IgE) autoantibodies target the BP180 and BP230 hemidesmosomal proteins, splitting the dermoepidermal junction and producing tense, subepidermal blisters, usually in older adults.

  • What are the typical symptoms?

    Most people start with weeks or months of intense itch and red, urticarial or eczema-like patches. Tense fluid-filled blisters then appear on the flexures, trunk and limbs. Mucosal involvement is uncommon, and the Nikolsky sign is negative - the skin does not shear apart under gentle pressure.

  • Which medications can trigger it?

    DPP-4 inhibitor gliptins (vildagliptin, linagliptin, sitagliptin) are the best-known trigger. Spironolactone, furosemide, penicillins, sulfa drugs, immune checkpoint inhibitors (nivolumab, pembrolizumab), tetanus vaccination, radiotherapy and ultraviolet light have all been linked as well.

  • How is bullous pemphigoid diagnosed?

    The diagnosis combines clinical features with a skin biopsy showing a subepidermal blister with eosinophils, direct immunofluorescence on perilesional skin (linear IgG and C3 at the dermoepidermal junction - the gold standard), indirect immunofluorescence on salt-split skin and ELISA for BP180 and BP230 antibodies.

  • What is the first-line treatment?

    Super-potent topical corticosteroid - clobetasol 0.05% cream, around 30 to 40 g a day - is first-line for most patients. A landmark New England Journal of Medicine trial showed it is as effective as oral prednisolone with fewer side effects. Oral prednisolone is reserved for severe, extensive or refractory disease.

  • What is the prognosis?

    Bullous pemphigoid is a serious disease in older adults, with one-year mortality reported between around 11% and 30% in some series - largely driven by age, frailty, comorbidity and the side effects of long-term immunosuppression. Modern topical-first regimens and steroid-sparing agents like doxycycline and rituximab are improving outcomes.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.